Skip to main content

NBIX

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

NBIX Price
Price Chart

Forward-looking statistics

Beta
0.60
Risk
39.21%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees1K
Market cap$13.6B

Fundamentals

Enterprise value$12.0B
Revenue$2.4B
Revenue per employee
Profit margin12.68%
Debt to equity19.45

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.94
Dividend per share
Revenue per share$24.04
Avg trading volume (30 day)$121M
Avg trading volume (10 day)$117M
Put-call ratio

Macro factor sensitivity

Growth+3.2
Credit-0.6
Liquidity+0.4
Inflation+0.9
Commodities+0.6
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio20.79
Price to sales5.30
P/E Ratio20.79
Enterprise Value to Revenue4.97
Price to book5.04

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend dayDecember 29, 1995

News

CPRX vs. NBIX: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research (June 23, 2025)
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

Neurocrine Biosciences Inc. NBIX stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings.

Benzinga (May 6, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free